|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aerovate Therapeutics, Inc. (AVTE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
27,670,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Co.'s initial focus is on improving AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
198,525 |
283,422 |
343,887 |
1,083,676 |
| Total Sell Value |
$5,199,454 |
$6,632,651 |
$7,649,183 |
$16,638,542 |
| Total People Sold |
6 |
7 |
7 |
8 |
| Total Sell Transactions |
25 |
38 |
50 |
111 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Niven Ralph |
Chief Scientific Officer |
• – – |
2022-08-18 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-16 |
4 |
AS |
$22.44 |
$482,932 |
D/D |
(21,000) |
0 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-16 |
4 |
OE |
$1.74 |
$36,540 |
D/D |
21,000 |
21,000 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-11 |
4 |
AS |
$23.89 |
$32,232 |
D/D |
(1,347) |
0 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-11 |
4 |
OE |
$1.74 |
$2,344 |
D/D |
1,347 |
1,347 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-10 |
4 |
AS |
$24.06 |
$306,366 |
D/D |
(12,720) |
0 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-10 |
4 |
OE |
$1.74 |
$22,133 |
D/D |
12,720 |
12,720 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-09 |
4 |
AS |
$23.84 |
$209,325 |
D/D |
(8,700) |
0 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-09 |
4 |
OE |
$1.74 |
$15,138 |
D/D |
8,700 |
8,700 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-08 |
4 |
AS |
$24.39 |
$170,962 |
D/D |
(6,943) |
0 |
|
- |
|
| Dake Benjamin T |
See Remarks |
• – – |
2022-08-08 |
4 |
OE |
$1.74 |
$12,081 |
D/D |
6,943 |
6,943 |
|
- |
|
| Atlas Venture Fund Xii, L.p. |
10% Owner |
– – • |
2022-07-15 |
4 |
AS |
$0.00 |
$0 |
D/D |
(310,388) |
2,327,909 |
|
- |
|
| Atlas Venture Fund Xii, L.p. |
10% Owner |
– – • |
2022-04-01 |
4 |
AS |
$0.00 |
$0 |
D/D |
(465,582) |
2,638,297 |
|
- |
|
| Cormorant Private Healthcare Fund Ii, Lp |
Former 10% Owner |
– – – |
2021-07-02 |
4 |
B |
$14.00 |
$7,000,000 |
I/I |
500,000 |
2,030,691 |
0.01 |
- |
|
| Cormorant Private Healthcare Fund Ii, Lp |
Former 10% Owner |
– – – |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,530,691 |
1,530,691 |
|
- |
|
| Grayzel David S. |
Director |
– • – |
2021-07-02 |
4 |
B |
$14.00 |
$7,499,996 |
I/I |
535,714 |
3,103,879 |
2.1 |
- |
|
| Grayzel David S. |
Director |
– • – |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,568,165 |
2,568,165 |
|
- |
|
| Atlas Venture Associates Xii, Llc |
10% Owner |
– – • |
2021-07-02 |
4 |
B |
$14.00 |
$7,499,996 |
D/D |
535,714 |
3,103,879 |
2.45 |
- |
|
| Atlas Venture Associates Xii, Llc |
10% Owner |
– – • |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,568,165 |
2,568,165 |
|
- |
|
| Healy James |
10% Owner |
– – • |
2021-07-02 |
4 |
B |
$14.00 |
$4,999,988 |
D/D |
357,142 |
3,758,686 |
2.45 |
- |
|
| Healy James |
10% Owner |
– – • |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,401,544 |
3,401,544 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
5,236,801 |
311,170 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2021-07-02 |
4 |
B |
$14.00 |
$38,999,996 |
I/I |
2,785,714 |
6,965,568 |
2.25 |
- |
|
| Katabi Maha |
Director |
– • • |
2021-07-02 |
4 |
B |
$14.00 |
$4,999,988 |
I/I |
357,142 |
3,758,686 |
2.25 |
- |
|
| Katabi Maha |
Director |
– • • |
2021-07-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,401,544 |
3,401,544 |
|
- |
|
225 Records found
|
|
Page 9 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
